Friday, March 13, 2015

Allergen Research Takes Aim At Peanut Allergies With $80M

San Mateo-based Allergen Research, which is developing desensitization treatments for food allergies, said Thursday that it has raised $80M in a Series B funding. The biopharmaceuticals firm said the funding goes towards a Phase 3 clinical trail of its lead product, aimed at treating peanut allergies. The funding was led by Foresite Capital, and also included Longitude Capital, Fidelity Management & Research Company, Aisling Capital, Adage Capital, RA Capital Management and Palo Alto Investors. Jim Tananbaum of Foresite and Stacey Seltzer of Aisling join the company's board with the funding.